Please Note: This trial is no longer enrolling new participants
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive
| Protocol No. | CTO-8951-CL-0305 | Scope | National |
|---|---|---|---|
| Principal Investigator | Shadia Jalal | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
